PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

~Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT05868226

Phase 2

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141

Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, …

Breast CancerHER2-positive Breast CancerER Positive Breast Cancer+1 more

~Estimated

~$10 – $7,500

Ruth O'ReganNCT04886531

Observational

Supporting Health Including Endocrine Treatment for Long Duration: A Pilot Intervention

This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) an…

Breast CancerBreast Cancer - FemaleBreast Carcinoma+2 more

~Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07482384